The Future of Febuxostat After the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) Trial: Who CARES?

Expert Opinion on Pharmacotherapy - United Kingdom
doi 10.1080/14656566.2018.1532503
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Urate-Lowering Efficacy and Safety of Febuxostat in the Treatment of the Hyperuricemia of Gout: The CONFIRMS Trial

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2010English

The Treatment of Patients With Parkinson's Desease: Who Cares?

Practical Neurology
MedicineNeurology
2005English

Who Cares?

2011English

Efficacy and Safety of Febuxostat in Elderly Female Patients

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2014English

Simultaneous Spectrophotometric Determination of Febuxostat and Allopurinol in Synthetic Mixture

International Research Journal of Pharmacy
2016English

Comparison of Febuxostat and Allopurinol for Hyperuricemia in Cardiac Surgery Patients With Chronic Kidney Disease (NU-FLASH Trial for CKD)

Journal of Cardiology
Cardiovascular MedicineCardiology
2015English

Discogenic Pain: Who Cares?

Health
2013English

Febuxostat in the Therapy of Gout: From Theory to Practice

Modern Rheumatology Journal
2017English

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)

Annals of Thoracic and Cardiovascular Surgery
GastroenterologyCardiologyCardiovascular MedicineMedicinePulmonaryRespiratory MedicineSurgery
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy